BALA CYNWYD, Pa., Nov. 16, 2023 (GLOBE NEWSWIRE) — Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
WaveDancer, Inc. (Nasdaq – WAVD)
Under the terms of the agreement, WaveDancer will merge with Firefly Neuroscience, Inc. (“Firefly”) in an all-stock transaction. Each share of Firefly common stock issued and outstanding will be converted into common stock of WaveDancer based on a fixed exchange ratio. At the effective time of the merger, securityholders of Firefly will own approximately 92% of the combined company and securityholders of WaveDancer will own approximately 8% of the combined company. The investigation concerns whether the WaveDancer Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution of the Company’s shareholders in the combined company.
Additional information can be found at https://www.brodskysmith.com/cases/wavedancer-inc-nasdaq-wavd/.
Selecta Biosciences, Inc. (Nasdaq – SELB)
Under the terms of the agreement, Selecta will merge with Cartesian Therapeutics, Inc. (“Cartesian”) in an all-stock transaction. At the effective time of the merger, securityholders of Cartesian will own approximately 73.1% of the combined company and securityholders of Selecta Biosciences will own approximately 26.9% of the combined company. The investigation concerns whether the Selecta Biosciences Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution of the Company’s shareholders in the combined company.
Additional information can be found at https://www.brodskysmith.com/cases/selecta-biosciences-inc-nasdaq-selb/.
Graphite Bio, Inc. (Nasdaq – GRPH)
Under the terms of the agreement, Graphite Bio will merge with LENZ Therapeutics in an all-stock transaction. Under the terms of the merger agreement, securityholders of LENZ Therapeutics will own approximately 65% of the combined company and securityholders of Graphite Bio will own approximately 35% of the combined company. The investigation concerns whether the Graphite Bio Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution of the Company’s shareholders in the combined company.
Additional information can be found at https://www.brodskysmith.com/cases/graphite-bio-inc-nasdaq-grph/.
CapStar Financial Holdings, Inc. (Nasdaq – CSTR)
Under the terms of the Merger Agreement, CapStar will be acquired by Old National Bancorp (“Old National”) (Nasdaq – ONB) in an all-stock transaction. Each outstanding share of CapStar common stock will be converted into the right to receive 1.155 shares of Old National common stock, valuing the transaction at approximately $344.4 million, or $16.64 per share, based on Old National’s 30-day volume weighted average closing stock price ending October 25, 2023. The investigation concerns whether the CapStar Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Old National is paying fair value to shareholders of the Company. For example, the deal consideration is below the 52-week high of $18.52 for the Company’s shares.
Additional information can be found at https://www.brodskysmith.com/cases/capstar-financial-holdings-inc-nasdaq-cstr/.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
- Catheter Precision, Inc. Announces First Quarter 2025 Update and Financial Results - May 14, 2025
- FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update - May 14, 2025
- Crescent Capital BDC, Inc. Reports First Quarter 2025 Earnings Results; Declares a Second Quarter Base Dividend of $0.42 Per Share - May 14, 2025
